Needham Reiterates Buy on Avadel Pharmaceuticals, Maintains $22 Price Target

Benzinga · 10/18 09:53
Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and maintains $22 price target.